Guidelines on the use of methotrexate in psoriasis;Metotrexato: Guía de uso en psoriasis

Actas Dermo-Sifiliograficas

Volumn 101, Issue 7, 2010, Pages 600-613

  Carretero, G ^a   Puig, L ^b   Dehesa, L ^a   Carrascosa, J M ^c   Ribera, M ^d   Sanchez Regana M ^e   Dauden E ^f   Vidal, D ^g   Alsina, M ^h   Munoz Santos C ^h   Lopez Estebaranz J L ⁱ   Notario, J ^j   Ferrandiz, C ^c   Vanaclocha, F ^k   Garcia Bustinduy M ^l   Taberner, R ^m   Belinchon I ⁿ   Sanchez Carazo J ^o   Moreno, J C ^p  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d Hospital Universitari de Sabadell   (Spain)

^e HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g Hospital de Sant Joan Despi Moises Broggi   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^j HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^l HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^m Hospital Son Lltzer   (Spain)

ⁿ HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^o HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^p Hospital Reina Sofa   (Spain)

more..

Author keywords

Guidelines; Methotrexate; Psoriasis; Treatment

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CEFALOTIN; COLCHICINE; CYCLOSPORIN; CYTARABINE; ETANERCEPT; ETRETIN; INFLIXIMAB; LIDAPRIM; METHOTREXATE; PENICILLIN G; PYRIMETHAMINE; RETINOID; TETRACYCLINE; USTEKINUMAB;

DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GENETIC PREDISPOSITION; HUMAN; LONG TERM CARE; LUNG TOXICITY; PRACTICE GUIDELINE; PSORIASIS; QUALITY OF LIFE; REVIEW; SPAIN; ULTRAVIOLET RADIATION;

EID: 77956839038     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S1578-2190(10)70682-X     Document Type: Review

References (79)

1. R. Gubner, S. August, and V. Ginsberg Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis Am J Med Sci 221 1951 176 182
2. W.F. Edmunson, and W.B. Guy Treatment of psoriasis with folic acid antagonists AMA Arch Derm 78 1958 200 203
3. B.N. Cronstein, D. Naime, and E. Ostad The anti-inflammatory effects of methotrexate are mediated by adenosine Adv Exp Med 370 1994 411 416
4. R.B. Warren, and C.E.M. Griffiths Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine Clin Dermatol 26 2008 438 447
5. L. Genestier, R. Paillot, S. Fournel, C. Ferraro, P. Miossec, and J.P. Revillard Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells J Clin Invest 102 1998 322 328
6. A. Johnston, J.E. Gudjonsson, H. Sigmundsdottir, B.R. Ludviksson, and H. Valdimarsson The anti-inflammatory action of methotexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adheson molecules Clin Immunol 114 2005 154 163
7. B. Torres-lvarez, J.P. Castanedo-Cazares, C. Fuentes-Ahumada, and B. Moncada The effect of methotrexate on the expression of cell adhesion molecules and activation molecule CD69 in psoriasis J Eur Acad Dermatol Venereol 21 2007 334 339
8. H. Sigmundsdottir, A. Johnston, J.E. Gudjonsson, B. Bjarnason, and H. Valdimarsson Methotrexate markedly reduces the expression of vascular E-selectin, cutaneous lymphocyte-associated antigen and the numbers of mononuclear leucocytes in psoriatic skin Exp Dermatol 13 2004 426 434
9. R.N. Maini, F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Davis, and J.D. Macfarlane Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 1998 1552 1563
10. S. Vermeire, M. Noman, G. Van Assche, F. Baert, G. D'Haens, and P. Rutgeerts Effectivenes of of concomitnat immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease Gut 56 2007 12263
11. D.W. Kress Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis J Am Acad Dermatol 54 Suppl 2006 S126 S128
12. M.E. Lloyd, M. Carr, P. McElhatton, G.M. Hall, and R.A. Hughes The effects of methotrexate on pregnancy, fertility and lactation QJM 92 1999 551 563
13. R.E. Kalb, B. Strober, G. Weinstein, and M. Lebwohl Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference J Am Acad Dermatol 60 2009 824 837
14. A. Nyfords, and H. Brodthagen Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy Dermatologica 140 1970 345 355
15. G.D. Weinstein, and P. Frost Methotrexate for psoriasis. A new therapeutic schedule Arch Dermatol 103 1971 33 38
16. J. Braun, P. Kstner, P. Flaxenberg, J. Whrisch, P. Hanke, and W. Demary Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, doule-blind, controlled, phase IV trial Arthritis Rheum 58 2008 73 81
17. V.M. Heydendael, P.I. Spuls, B.C. Opmeer, C.A. de Borgie, J.B. Reitsma, and W.F. Goldschmidt Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis N Engl J Med 349 2003 658 665
18. I. Flytstrom, B. Stenberg, and A. Svensson Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial Br J Dermatol 158 2008 116 121
19. J.H. Saurat, G. Stingl, L. Dubertret, K. Papp, R.G. Langley, and J.P. Ortonne Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 2008 558 566
20. Disponible en: http://www.clinicalstudyresults.org/documents/company- study-9522-0.pdf (Estudio RESTORE)
21. J. Schmitt, Z. Zhang, G. Wozel, M. Meurer, and W. Kirch Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials Br J Dermatol 159 2008 513 526
22. N. Bansback, S. Sizto, H. Sun, S. Feldman, M.K. Willian, and A. Anis Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis Dermatology 219 2009 209 218
23. D. Pathirana, A.D. Ormerod, P. Saiag, C. Smith, P.I. Spuls, and A. Nast European S3-Guidelines on the systemic treatment of psoriasis vulgaris J European Acad Dermatol 23 Suppl 2 2009 5 70
24. R.J. Van Dooren-Greebe, A.L. Kuijpers, J. Mulder, T. De Boo, and P.C. Van de Kerkhof Methotrexate revisited: effects of long-term treatment in psoriasis Br J Dermatol 130 1994 204 210 (Pubitemid 24204616)
25. U.F. Haustein, and M. Rytter Methotrexate in psoriasis: 26 years experience with low-dose long-term treatment J Eur Acad Dermatol Venereol 14 2000 382 388
26. J. Lucas, E. Ntuen, D.J. Pearce, A.B. Fleischer Jr, and S.R. Feldman Methotrexate: Understanding the risk in psoriasis patients J Dermatolog Treat 1 2009 1 3
27. R.J. McKendry The remarkable spectrum of methotrexate toxicities Rheum Dis Clin North Am 23 1997 939 954
28. A.E. Van Ede, R.F. Laan, M.J. Rood, T.W. Huizinga, M.A. van de Laar, and C.J. van Denderen Effect or folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study Arthritis Rheum 44 2001 1515 1524
29. A. MacDonald, and A.D. Burden Noninvasive monitoring for methotrexate hepatotoxicity Br J Dermatol 152 2005 405 408
30. o 6-2004.
31. Improving compliance with oral methotrexate guidelines Disponible en: http://www.nrls.npsa.nhs.uk/resources/patient-safety-topics. [consultado 22/2/2010], [actualizado 1/1/2007]
32. R.B. Warren, Smith, E. Campalani, S. Eyre, C.H. Smith, and J.N.W.N. Barker Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms Br J Dermatol 160 2009 438 441
33. T. Dervieux, D. Orentas, J. Marcelletti, K. Pischel, K. Smith, and M. Walsh HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis Clin Chem 49 2003 1632 1641
34. E. Campalani, M. Arenas, A.M. Marinaki, C.M. Lewis, J.N. Barker, and C.H. Smith Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis J Invest Dermatol 127 2007 1860 1867
35. R.B. Warren, R.L. Smith, E. Campalani, C.H. Smith, J.N. Barker, and J. Worhington Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis J Invest Dermatol 128 2008 1925 1929
36. M. Hroch, J. Chladek, M. Simkova, J. Vaneckova, J. Grim, and J. Martinkova A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment J Eur Acad Dermatol Venereol 22 2008 19 24
37. J. Chldek, M. Simkov, J. Vaneckov, M. Hroch, J. Jirina Chldkova, and J. Martnkov The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis Eur J Clin Pharmacol 64 2008 347 355
38. S.A. Alkins, J.C. Byrd, S.K. Morgan, F.T. Ward, and R.B. Weiss Anaphylactoid reactions to methotrexate Cancer 77 1996 2123 2126
39. H.H. Roenigk Jr, R. Auerbach, H. Maibach, G Weinstein, and M Lebwohl Methotrexate in psoriasis: consensus conference J Am Acad Dermatol 38 1998 478 485
40. J.M. Kremer, G.S. Alarcn, R.W. Lightfoot Jr, R.F. Willkens, D.E. Furst, and H.J. Williams Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology Arthritis Rheum 37 1994 316 328
41. M.A. Berends, J. Snoek, E.M. de Jong, P.C. van de Kerkhof, M.G. van Oijen, and J.H. van Krieken Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent Aliment Pharmacol Ther 24 2006 805 811
42. J.S. Henning, L.M. Gruson, and B.E. Strober Reconsidering liver biopsies during methotrexate therapy J Am Acad Dermatol 56 2007 893 894
43. P. Gisondi, G. Targher, G. Zoppini, and G. Girolomoni Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis J Hepatol 51 2009 758 764
44. I.J. Hickman, and G.A. Macdonald Impact of diabetes on the severity of liver disease Am J Med 120 2007 829 834
45. K. Lindsay, A.D. Fraser, A. Layton, M. Goodfield, H. Gruss, and A. Gough Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy Rheumatology (Oxford) 48 2009 569 572
46. R.J. Chalmers, B. Kirby, A. Smith, P. Burrows, R. Little, and M. Horan Replacement of routine liver biopsy by procollagen III aminipeptide for montoring patients whit psoriasis receiveing long-term methotrexate: a multicenter audit and health economic analysis Br J Dermatol 152 2005 444 450
47. P.D. Maurice, A.J. Maddox, C.A. Green, F. Tatnall, J.K. Schofield, and D.J. Stott Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen Br J Dermatol 152 2005 451 458
48. D. Laharie, F. Zerbib, X. Adhoute, X. Bou-Lahorgue, J. Foucher, and L. Castra l. Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate Aliment Pharmacol Ther 23 2006 1621 1628
49. M.A. Berends, J. Snoek, E.M. de Jong, J.H. Van Krieken, R.J. de Knegt, and M.G. van Oijen Biochemical and biophysical assessment of MTX-induced liber fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan pedicts the absence of significant liver fibrosis Liver Int 27 2007 639 645
50. S. Khan, D. Subedi, and M.M.U. Chowdhury Use of amino terminal type III procollagen peptide assay in methotrexate therapy for psoriasis Postgrad Med J 82 2006 353 354
51. J.M. Kremer, G.S. Alarcn, M.E. Weinblatt, N.I.V. Haymakcian, M. Macaluso, and G.V. Cannon Clinical, laboratory, rafiographic, and histopathologic features of methotrexate associated lung injury inpatients with rheumatoid arthritis Arthritis Rheum 40 1997 18297
52. D. Senz Abad, F.J. Ruiz-Ruiz, S. Monn Ballarn, J. Mozota Duarte, and A. Marquina Barcos Neumonitis secundaria a metotrexate Ann Med Intern 25 2008 27 30
53. P. Hillquin, X. Renoux, X. Perrot, S. Puechal, and C.L. Menkes Ocurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis Br J Rheum 35 1996 441 445
54. G.S. Alarcon, A. Kremer, M. Macaluso, M.E. Weinblatt, G.W. Cannon, and W.R. Palmer Risk factors methotrexate-induced lung injury in patients with rheumatoid arthritis: A multicenter, case-control study Ann Intern Med 127 1997 356 364
55. E. From Methotrexate pneumonitis in a psoriatic Br J Dermatol 93 1975 107 110
56. A.J. Kinder, A.B. Hassell, J. Brand, A. Brownfield, M. Grove, and M.F. Shadforth The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions Rheumatology 44 2005 61 66
57. J. Belzunegui, J.J. Intxausti, J.R. De Dios, L. Lpez-Domnguez, R. Queiro, and C. Gonzlez Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate Clin Exp Rheumatol 19 2001 727 730
58. J.K. Dawson, D.R. Graham, J. Desmond, H.E. Fewins, and M.P. Lynch Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests Rheumatology (Oxford) 41 2002 262 267
59. L. Puig, X. Bordas, J.M. Carrascosa, E. Dauden, C. Ferrndiz, and J.M. Hernnz Documento de Consenso sobre la evaluacin y el tratamiento de la psoriasis modeada/grave del Grupo Espaol de Psoriasis de la Academia Espaola de Dermatologa y Venereologa Actas Dermosifiligr 100 2009 277 286
60. L. Dubertret, S. Climenti, E. Christophers, E. Dauden, M. de Rie, and C.E.M. Griffiths Alice, loi, Magali and Robert: the lives of four patients with psoriasis and the therapeutic approaches of eight European experts Br J Dermatol 161 Suppl. 2 2009 1 30
61. Disponible en: https://sinaem4.agemed.es/consaem/METOTREXATO. [consultado 17/2/2010].
62. S. Prey, and C. Paul Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review Br J Dermatol 160 2009 622 628
63. T.A. Goodman, and R.P. Polisson Methotrexate: adverse reactions and major toxicities Rheum Dis Clin North Am 20 1994 513 528
64. A.E. van Ede, R.F. Laan, M.J. Rood, T.W. Huizinga, M.A. van de Laar, and C.J. van Denderen Effect or folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study Arthritis Rheum 44 2001 1515 1524
65. A. Salim, E. Tan, A. Ilchyshyn, and J. Berth-Jones Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial Br J Dermatol 154 2006 1169 1174
66. R Manna, RM Verrechia, M Diaco, M Montalto, G Cammarota, and G Gasbarrini Folic acid supplementation during methotrexate treatment: nonsense? Rheumatology 43 2004 267 271
67. J.E. Baggott, and S.L. Morgan Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation Arthritis Rheum 60 2009 2257 2261
68. P.C.M. Van de Kerkhof Therapeutic strategies: rotational therapy and combinations Clin Exp Dermatol 26 2001 356 361
69. F. Aydin, T. Canturk, N. Senturk, and A.Y. Turanli Methotrexate and ciclosporin combination for the treatment of severe psoriasis Clin Exp Dermatol 31 2006 520 524
70. C.M. Clark, B. Kirby, A.D. Morris, S. Davison, I. Zaki, and R. Emerson Combination treatment with methotrexate and ciclosporin for severe recalcitrant psoriasis Br J Dermatol 141 1999 279 282 (Pubitemid 29397996)
71. P. Asawanonda, and Y. Nateetongrungsak Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study J Am Acad Dermatol 54 2006 1013 1018
72. K.E. Lowenthal, P.J. Horn, and R.E. Kalb Concurrent use of methotrexate and acitretin revisited J Dermatolog Treat 19 2008 22 26
73. W.G. Stebbins, and M.G. Lebwohl Biologics in combination with nonbiologics: efficacy and safety Dermatol Ther 17 2004 432 440
74. J.C. Cather, and A. Menter Combining traditional agents and biologics for the treatment of psoriasis Semin Cutan Med Surg 24 2005 37 45
75. U. Klotz, A. Teml, and M. Schwab Clinical pharmacokinetics and use of infliximab Clin Pharmacokinet 46 2007 645 660
76. C. Zachariae, N.J. Mørk, T. Reunala, H. Lorentzen, E. Falk, and S.L. Karvonen The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy Acta Derm Venereol 88 2008 495450
77. R.J. Driessen, P.C. van de Kerkhof, and E.M. de Jong Etanercept combined with methotrexate for high-need psoriasis Br J Dermatol 159 2008 460 463
78. D.D. Gladman, P.J. Mease, C.T. Ritchlin, EH Choy, JT Sharp, and PA Ory Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial Arthritis Rheum 56 2007 476 488
79. R.B. Warren, R.J.G. Chalmers, C.E.M. Griffiths, and A. Menter Methotrexate for psoriasis in the era of biological therapy Clin Exp Dermatol 33 2008 551 554